Photo from ASCO/X
Jun 13, 2024, 15:19
Recent news from Journal of Clinical Oncology about HR+/HER2-negative breast cancer – ASCO
ASCO (American Society of Clinical Oncology) shared a post on X/Twitter:
”Recent news from Journal of Clinical Oncology: Ribociclib + endocrine therapy represents a potential new 1L option for patients with HR+/HER2-negative advanced breast cancer.”
Source: ASCO/X
ASCO (American Society of Clinical Oncology) is a leading professional organization representing nearly 45,000 physicians and oncology specialists worldwide, dedicated to cancer care. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO is committed to advancing cancer research, education, prevention, and high-quality patient care.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 24, 2024, 00:40
Dec 24, 2024, 00:34
Dec 24, 2024, 00:32
Dec 24, 2024, 00:30
Dec 24, 2024, 00:27
Dec 24, 2024, 00:24
Dec 24, 2024, 00:16
Dec 23, 2024, 21:21
Dec 23, 2024, 21:19